What this quiz covers
This quiz focuses on Regulation Of Cell Cycle, giving you a quick way to practice the rules, question types, and explanations that matter most for AP Biology.
In a cell-free extract, cyclin binds CDK to form an active complex that phosphorylates multiple substrates. A phosphatase removes these phosphates, opposing CDK signaling. When cyclin concentration is held constant, adding a phosphatase inhibitor causes substrate phosphorylation to remain high for longer, even though CDK activity is unchanged. In intact cells, sustained phosphorylation of mitotic substrates correlates with delayed exit from mitosis. Which change would most likely shorten mitotic duration in cells treated with the phosphatase inhibitor?
AP Biology Quiz
Practice Regulation Of Cell Cycle in AP Biology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.
This quiz focuses on Regulation Of Cell Cycle, giving you a quick way to practice the rules, question types, and explanations that matter most for AP Biology.
Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.
In a cell-free extract, cyclin binds CDK to form an active complex that phosphorylates multiple substrates. A phosphatase removes these phosphates, opposing CDK signaling. When cyclin concentration is held constant, adding a phosphatase inhibitor causes substrate phosphorylation to remain high for longer, even though CDK activity is unchanged. In intact cells, sustained phosphorylation of mitotic substrates correlates with delayed exit from mitosis. Which change would most likely shorten mitotic duration in cells treated with the phosphatase inhibitor?
Explanation: This question assesses understanding of signaling-based regulation of the cell cycle, focusing on CDK-cyclin dynamics and phosphorylation balance during mitosis. The phosphatase inhibitor sustains high phosphorylation of mitotic substrates by preventing dephosphorylation, leading to delayed mitotic exit in intact cells. Reducing cyclin availability decreases CDK-dependent phosphorylation rates, allowing existing phosphatase activity to lower phosphorylation levels more quickly. This shortens mitotic duration by reducing the overall signaling strength opposing exit. A tempting distractor is B, which suggests decreasing APC/C activity to persist cyclin, but this would prolong high CDK activity, stemming from the misconception that inhibiting degradation accelerates exit rather than delays it. To approach similar problems, consider the balance between kinase and phosphatase activities and select changes that tip it toward the desired outcome.
A signaling module at the G2/M transition uses positive feedback: active CDK–cyclin activates a phosphatase that removes the CDK inhibitory phosphate, and simultaneously inhibits the kinase that adds the inhibitory phosphate. This creates a rapid switch from low to high CDK activity. A mutation prevents CDK from activating the phosphatase, but cyclin binding and the inhibitory-kinase inhibition remain normal. Which effect would most likely be observed in the mutant cells?
Explanation: This question assesses understanding of signaling-based regulation of the cell cycle, focusing on positive feedback in CDK activation at G2/M. The mutation prevents CDK from activating the phosphatase that removes its inhibitory phosphate, disrupting the feedback loop for rapid CDK activation. This results in a slower, less abrupt rise in CDK activity as inhibitory phosphate removal is impaired, delaying mitotic entry. The remaining inhibition of the kinase provides some activation but lacks the switch-like rapidity. A tempting distractor is D, which suggests faster entry due to phosphorylation accumulation, but accumulation inhibits, stemming from the misconception that losing positive feedback accelerates rather than slows transitions. To approach similar problems, dissect feedback mechanisms and evaluate how partial disruptions affect timing and sharpness of phase changes.
A cell-cycle checkpoint at metaphase monitors kinetochore attachment to spindle microtubules. When even one kinetochore is unattached, a signaling complex inhibits the anaphase-promoting complex/cyclosome (APC/C). When all kinetochores are attached, inhibition stops, APC/C becomes active, and APC/C tags securin for degradation; separase then cleaves cohesin, allowing sister chromatids to separate. In an experiment, cells are treated with a drug that keeps the inhibitory kinetochore signal active even after all kinetochores are attached. Which change would most likely affect chromosome segregation in treated cells?
Explanation: This question assesses understanding of signaling-based regulation of the cell cycle, specifically the metaphase checkpoint's control of APC/C activity. Normally, unattached kinetochores signal to inhibit APC/C, preventing securin degradation until all attachments occur, after which APC/C activates to allow chromatid separation. The drug maintains the inhibitory signal post-attachment, keeping APC/C inhibited and securin stable, thus delaying anaphase onset and affecting segregation, as stated in choice B. This mimics a persistent checkpoint activation despite proper attachments. A tempting distractor is choice A, proposing earlier separation from prolonged APC/C activity, but this reverses the drug's effect on inhibition, misconstruing signal persistence as activation. A transferable strategy is to map checkpoint signals to their targets and predict outcomes when signals are artificially sustained or disrupted.
In an in vitro assay, cyclin A–CDK2 phosphorylates a substrate required for progression through S phase. A second protein binds cyclin A–CDK2 and blocks access to the substrate without removing cyclin A. When this blocker is added to cells, DNA content analysis shows fewer cells with intermediate (between 2N and 4N) DNA. Which change would most likely restore S-phase progression while the blocker remains present?
Explanation: This question assesses understanding of signaling-based regulation of the cell cycle, specifically S-phase progression requiring cyclin A–CDK2 substrate phosphorylation. The blocker binds cyclin A–CDK2, preventing substrate access and reducing cells with intermediate DNA content. Adding a small molecule that prevents blocker binding, as in choice A, would restore substrate access and S-phase progression. This directly counters the blocker's mechanism in the assay. A tempting distractor is choice D, which proposes increasing cyclin A synthesis, but this misconceives that higher levels overcome binding without displacing the blocker. A transferable strategy is to use inhibitors that target accessory proteins rather than core complexes in signaling disruptions.
In a cultured mammalian cell line, entry into mitosis depends on a checkpoint where cyclin B binds Cdk1 to form active MPF. MPF activity rises sharply only when inhibitory phosphates on Cdk1 are removed by a phosphatase, and MPF activity falls when cyclin B is rapidly degraded by a ubiquitin-ligase complex activated later in mitosis. A researcher adds a small molecule that prevents removal of the inhibitory phosphates on Cdk1 without changing cyclin B abundance. Which change would most likely occur in cell cycle progression after treatment?
Explanation: This question assesses understanding of signaling-based regulation of the cell cycle, emphasizing the activation of mitosis-promoting factor (MPF) for G2/M transition. Normally, MPF forms when cyclin B binds Cdk1, but full activity requires removal of inhibitory phosphates by a phosphatase to trigger mitosis entry. The small molecule prevents this dephosphorylation, keeping Cdk1 inhibited even with cyclin B present, causing cells to accumulate in G2 without progressing to mitosis, as in choice A. This blocks the sharp rise in MPF activity needed for mitotic entry. A tempting distractor is choice B, suggesting early mitosis due to increased MPF, but this ignores the necessity of dephosphorylation for activation, confusing binding with full enzymatic function. A transferable strategy is to identify key activation steps in cyclin-CDK complexes and evaluate how inhibitors affect checkpoint passage.
A lab measures CDK activity using phosphorylation of a peptide substrate. In control cells, cyclin B–CDK1 activity is high in metaphase and then drops after APC/C activation. In a mutant, securin is present but cannot bind separase. APC/C activation and cyclin B degradation still occur normally. Which prediction is most consistent with the mutant's signaling state during metaphase-to-anaphase transition?
Explanation: This question assesses understanding of signaling-based regulation of the cell cycle, specifically securin's role in inhibiting separase until APC/C-mediated degradation. In the mutant, securin cannot bind separase, leaving separase uninhibited. This allows earlier cohesin cleavage, as in choice A, even with normal APC/C and cyclin B dynamics. The prediction fits the binding defect during the transition. A tempting distractor is choice B, which links cyclin B degradation to separase, but this misconceives the independent regulation of securin and cyclin B by APC/C. A transferable strategy is to isolate the functional impact of binding mutations on downstream effectors.
Cells exposed to a DNA-damaging agent activate a checkpoint kinase that phosphorylates and inhibits a Cdc25-like phosphatase. When inhibited, the phosphatase cannot remove inhibitory phosphates from Cdk1, keeping M-cyclin–Cdk1 inactive. In a follow-up treatment, a second drug blocks the checkpoint kinase's catalytic activity without affecting other kinases. The damaged DNA remains unrepaired during the observation window.
Which effect would most likely occur after adding the second drug?
Explanation: Signaling-based regulation of the cell cycle is a key skill in understanding how DNA damage checkpoints prevent mitotic entry with unrepaired DNA. The second drug blocks the checkpoint kinase, preventing inhibition of the Cdc25-like phosphatase, so inhibitory phosphates are removed from Cdk1, activating M-cyclin–Cdk1 and allowing mitotic entry despite damage. This overrides the normal G2 arrest signal. The damaged DNA persists, but the treatment removes the inhibitory block on phosphatase activity. A tempting distractor is choice B, suggesting S-phase arrest because APC/C is inhibited, but this confuses G2 checkpoint mechanisms with mitotic regulators, a misconception about phase-specific controls. To approach similar problems, trace how inhibiting an inhibitor affects the pathway's net output.
During G2, a CDK–cyclin complex is present but kept inactive by an inhibitory phosphate. When DNA damage is detected, signaling increases activity of the kinase that adds the inhibitory phosphate and decreases activity of the phosphatase that removes it, maintaining CDK inactivity. A mutant cell line cannot increase the inhibitory-kinase activity after DNA damage, but the phosphatase regulation is normal. Which effect is most likely in the mutant after DNA damage occurs?
Explanation: This question assesses understanding of signaling-based regulation of the cell cycle, focusing on DNA damage response and inhibitory phosphorylation of CDK in G2. The mutant cannot increase inhibitory-kinase activity after DNA damage, failing to reinforce CDK inhibition despite normal phosphatase regulation. This allows more cells to enter mitosis because the inhibitory phosphorylation is not sufficiently maintained, reducing the effectiveness of the G2 arrest signal. Consequently, CDK activation proceeds more readily despite damage. A tempting distractor is B, which suggests G1 arrest due to securin issues, but securin is mitotic, stemming from the misconception that G2 damage signals affect unrelated downstream proteins. To approach similar problems, evaluate how mutations disrupt feedback in damage responses and anticipate effects on cell cycle progression.
In cultured animal cells, entry into mitosis depends on activation of a cyclin-dependent kinase (CDK) by binding to mitotic cyclin and removal of an inhibitory phosphate by a phosphatase. A separate kinase adds the inhibitory phosphate, keeping the CDK inactive when conditions are unfavorable. Researchers add a small molecule that prevents the phosphatase from binding the CDK, while cyclin levels and ATP remain unchanged. Cells accumulate with duplicated DNA and intact nuclear envelopes, indicating arrest before mitosis. Which change would most likely restore progression into mitosis under these conditions?
Explanation: This question assesses understanding of signaling-based regulation of the cell cycle, focusing on CDK activation for mitotic entry. The small molecule prevents the phosphatase from removing the inhibitory phosphate on CDK, causing cells to arrest in G2 with duplicated DNA and intact nuclear envelopes despite cyclin presence. Adding a CDK variant that cannot be inhibited by phosphorylation at the inhibitory site bypasses the need for dephosphorylation, allowing cyclin-bound CDK to remain active. This restores progression into mitosis by circumventing the block in the activation pathway. A tempting distractor is A, which suggests increasing the inhibitory kinase activity, but this would further inhibit CDK, stemming from the misconception that enhancing negative regulation could promote activation. To approach similar problems, identify the blocked regulatory step and select interventions that directly bypass it without reinforcing inhibition.
A lab uses a fluorescent reporter that increases signal when Cdk1 phosphorylates a specific peptide. In control cells, reporter fluorescence rises sharply at mitotic entry and falls at mitotic exit. In experimental cells, fluorescence rises normally but fails to fall, and cells do not reform nuclear envelopes. APC/C substrate tagging is normal, but proteasome function is impaired.
Which molecular signaling state best matches the experimental cells?
Explanation: Signaling-based regulation of the cell cycle is a key skill in understanding how degradation is essential for activity shifts, like mitotic exit. Impaired proteasome function allows APC/C tagging but prevents M-cyclin degradation, sustaining Cdk1 signaling and high fluorescence, blocking envelope reformation. This matches the persistent phosphorylation observed. Tagging alone isn't sufficient; removal is needed. A tempting distractor is choice B, claiming reduced signaling from cyclin removal, but inhibition stabilizes cyclins, misconstruing blockage as enhancement of degradation. To approach similar problems, differentiate between preparatory tagging and the degradative step in regulation.
At the G1/S transition, an inhibitor protein binds cyclin E–CDK2 and prevents its kinase activity. A signaling event normally phosphorylates the inhibitor, causing it to dissociate from cyclin E–CDK2. In mutant cells, the inhibitor cannot be phosphorylated, and cyclin E–CDK2 activity remains low despite normal cyclin E levels. Which change would most likely increase S-phase entry in the mutant cells?
Explanation: This question assesses understanding of signaling-based regulation of the cell cycle, specifically the G1/S transition where an inhibitor blocks cyclin E–CDK2 until phosphorylated and dissociated. In mutants, the unphosphorylatable inhibitor keeps cyclin E–CDK2 inactive, preventing S-phase entry. Introducing a cyclin E–CDK2 complex that cannot bind the inhibitor, as in choice B, would maintain kinase activity and promote S-phase entry. This bypasses the mutation's effect on the signaling event described. A tempting distractor is choice E, which suggests increasing cyclin E transcription, but this misconceives that higher levels overcome binding without preventing inhibitor interaction. A transferable strategy is to engineer variants that evade inhibitory binding when normal signaling fails.
A lab compares two treatments in synchronized G2 cells. Treatment 1 increases M-cyclin concentration; treatment 2 increases activity of a Cdk1-inhibitory kinase that adds an inhibitory phosphate to Cdk1. In both cases, M-cyclin can bind Cdk1. Nuclear envelope breakdown occurs only when active M-cyclin–Cdk1 exceeds a threshold.
Which treatment is more likely to delay nuclear envelope breakdown?
Explanation: Signaling-based regulation of the cell cycle is a key skill in understanding how molecular concentrations and modifications set thresholds for events like nuclear envelope breakdown. Treatment 2 increases inhibitory kinase activity, adding more inhibitory phosphates to Cdk1 and reducing active M-cyclin–Cdk1 below the threshold, delaying breakdown. Treatment 1 raises M-cyclin but doesn't address phosphorylation, while treatment 2 directly lowers activity. Both allow binding, but inhibition dominates in treatment 2. A tempting distractor is choice C, claiming treatment 1 delays because M-cyclin prevents phosphorylation, but this confuses cyclin binding with inhibition relief, a misconception about complex dynamics. To approach similar problems, compare how each intervention affects the net activity crossing a threshold.
A researcher adds a nonhydrolyzable ATP analog that binds a CDK's active site but cannot be used for phosphate transfer. Cyclin binding and CDK phosphorylation states are unchanged, but kinase activity toward substrates is reduced. Cells accumulate before entering S phase. Which change would most likely allow progression into S phase while the ATP analog remains present?
Explanation: This question assesses understanding of signaling-based regulation of the cell cycle, specifically ATP-dependent phosphate transfer in CDK catalysis for S-phase entry. The nonhydrolyzable ATP analog binds but blocks transfer, reducing substrate phosphorylation and causing pre-S accumulation. Providing an alternative kinase phosphorylating the same substrates with normal ATP, as in choice A, would restore progression. This bypasses the CDK block in the stimulus. A tempting distractor is choice E, which suggests increasing cyclin levels, but this misconceives that more complex overcomes ATP site occupancy. A transferable strategy is to introduce redundant effectors when core catalytic mechanisms are impaired.
A checkpoint protein binds and inhibits a G1/S cyclin–Cdk complex. When a signaling kinase phosphorylates the checkpoint protein, the inhibitor is targeted for rapid removal by a ubiquitin ligase, freeing cyclin–Cdk activity. A mutation prevents the checkpoint protein from binding the ubiquitin ligase but does not affect phosphorylation.
Which effect is most likely in the mutant cells?
Explanation: Signaling-based regulation of the cell cycle is a key skill in understanding how degradation relieves inhibition at transitions like G1/S. The mutation prevents ubiquitin ligase binding, so the phosphorylated inhibitor persists, continuing to block cyclin–Cdk and delaying S-phase entry. Phosphorylation occurs but doesn't lead to removal. This sustains inhibition despite signaling. A tempting distractor is choice B, claiming accelerated entry because phosphorylation removes inhibition, but this ignores the need for degradation, a misconception about modification versus clearance. To approach similar problems, check if the pathway requires both tagging and actual removal for relief.
A sensor protein at kinetochores recruits checkpoint proteins when microtubules are unattached, generating a diffusible inhibitor of APC/C. In a mutant, the sensor cannot recruit checkpoint proteins even when kinetochores are unattached. During mitosis, many chromosomes remain unattached, but APC/C is not inhibited. Which outcome is most likely in the mutant cells?
Explanation: This question assesses understanding of signaling-based regulation of the cell cycle, specifically the spindle checkpoint where unattached kinetochores inhibit APC/C via recruited proteins. The mutant sensor fails to recruit inhibitors, allowing APC/C activity despite unattached kinetochores. This leads to securin degradation and anaphase with missegregation, as in choice A, causing errors. The outcome reflects the loss of checkpoint signaling in the stimulus. A tempting distractor is choice D, which predicts metaphase arrest, but this misconceives that failed recruitment strengthens rather than weakens inhibition. A transferable strategy is to predict checkpoint failures by tracing signal generation to effector inhibition.
Cyclin levels can change rapidly when cyclins are tagged for degradation by ubiquitin ligases. In a population of dividing cells, cyclin B normally drops sharply at the metaphase-to-anaphase transition due to APC/C-mediated ubiquitination. A mutation reduces APC/C ubiquitin-ligase activity but does not affect microtubule attachment to kinetochores. Which effect is most likely observed in the mutant cells?
Explanation: This question assesses understanding of signaling-based regulation of the cell cycle, specifically how APC/C-mediated ubiquitination controls cyclin levels for mitotic exit. The mutation reduces APC/C activity, preventing sharp cyclin B degradation at the metaphase-to-anaphase transition. This results in prolonged high cyclin B–CDK1 activity and delayed mitotic exit, as in choice A, despite normal kinetochore attachment. The effect stems from impaired ubiquitination in the stimulus. A tempting distractor is choice C, which predicts immediate anaphase, but this misconceives that reduced APC/C accelerates rather than hinders securin degradation. A transferable strategy is to consider how ligase mutations disrupt degradation timing and extend phase-specific activities.
At the spindle checkpoint, a kinetochore-associated complex generates an inhibitor that binds APC/C and prevents ubiquitination of securin. When all chromosomes are properly attached, inhibitor production stops and APC/C becomes active. A mutation causes continuous inhibitor production even after all kinetochores are attached and under tension.
Which outcome is most likely in mutant cells?
Explanation: Signaling-based regulation of the cell cycle is a key skill in understanding how the spindle checkpoint ensures alignment before anaphase. Continuous inhibitor production keeps APC/C inhibited even after attachment, preventing securin ubiquitination and causing metaphase arrest with persistent securin. Chromatids cannot separate without securin removal. The mutation overrides the normal shutdown of signaling upon attachment. A tempting distractor is choice D, suggesting bypassing mitosis because M-cyclin is destroyed early, but this assumes APC/C activation, misconstruing persistent inhibition as premature activity. To approach similar problems, identify if the defect sustains or abolishes checkpoint signaling.
A cell-cycle inhibitor protein is normally degraded after being ubiquitinated by an E3 ligase, allowing cyclin D–CDK4/6 to become active. A mutation prevents the inhibitor from being ubiquitinated, so it persists and continues binding CDK4/6. Flow cytometry shows many cells remain in G1 with 2N DNA. Which change would most likely increase progression into S phase in the mutant cells?
Explanation: This question assesses understanding of signaling-based regulation of the cell cycle, specifically ubiquitination controlling inhibitor degradation for cyclin D–CDK4/6 activation. The mutation prevents ubiquitination, allowing the inhibitor to persist and bind CDK4/6, causing G1 arrest. Introducing a CDK4/6 variant that cannot bind the inhibitor, as in choice A, would free CDK4/6 and promote S-phase entry. This evades the persistent inhibitor in the mutants. A tempting distractor is choice E, which suggests increasing E3 ligase transcription, but this misconceives that more ligase overcomes a ubiquitination-defective mutation. A transferable strategy is to alter binding interfaces to prevent inhibitory interactions when degradation fails.
A cell-cycle checkpoint uses a phosphatase to activate a CDK by removing an inhibitory phosphate. A mutation increases the phosphatase's activity, causing faster removal of the inhibitory phosphate on CDK1. Cyclin B levels are unchanged. Which change is most likely in the mutant cells' cell-cycle timing?
Explanation: This question assesses understanding of signaling-based regulation of the cell cycle, specifically phosphatase-mediated removal of inhibitory phosphates at checkpoints. The mutation increases phosphatase activity, accelerating CDK1 dephosphorylation without changing cyclin B. This shortens G2 via earlier cyclin B–CDK1 activation, as in choice A, advancing mitosis. The change reflects faster inhibitory removal in the stimulus. A tempting distractor is choice C, which predicts delayed anaphase, but this misconceives that higher CDK1 inhibits APC/C rather than promoting entry. A transferable strategy is to predict timing shifts by evaluating enzyme activity changes on key regulators.
Cells treated with a microtubule-depolymerizing drug show many unattached kinetochores. The spindle checkpoint signal inhibits APC/C, stabilizing securin and cyclin B. A second compound is added that forces APC/C to remain active even when checkpoint signaling is present. Which outcome is most likely with both drugs present?
Explanation: This question assesses understanding of signaling-based regulation of the cell cycle, specifically the spindle checkpoint inhibiting APC/C in response to unattached kinetochores. The microtubule drug creates unattached kinetochores, but the second compound forces APC/C activity, overriding inhibition. This causes chromatid separation with errors, as in choice A, due to missegregation. The outcome stems from checkpoint bypass in the stimulus. A tempting distractor is choice C, which predicts metaphase arrest, but this misconceives that forced APC/C sustains rather than overcomes inhibition. A transferable strategy is to combine perturbations to evaluate checkpoint robustness and failure modes.